DALCOR PHARMA LICENSES A LATE-STAGE INVESTIGATIONAL CARDIOVASCULAR DRUG FOLLOWING MAJOR DISCOVERY BY MONTREAL HEART INSTITUTE (MHI) SCIENTISTS
Montreal (ots/PRNewswire) - - New company DalCor to sponsor global phase III clinical trial to be led by MHI DalCor Pharmaceuticals Canada Inc. (DalCor) and the Montreal Heart Institute (MHI) announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a ...
mehr